Effects of low-dose oxygen ions on cardiac function and structure in female C57BL/6J mice

2022 ◽  
Author(s):  
Ashley Nemec-Bakk ◽  
Vijayalakshmi Sridharan ◽  
Reid D Landes ◽  
Preeti Singh ◽  
Maohua Cao ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Low Dose ◽  
Oxygen Ions

scholarly journals Effects of low-dose oxygen ions and protons on cardiac function and structure in male C57BL/6J mice

2019 ◽  
Vol 20 ◽  
pp. 72-84 ◽  
Author(s):  
John W Seawright ◽  
Vijayalakshmi Sridharan ◽  
Reid D Landes ◽  
Maohua Cao ◽  
Preeti Singh ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Low Dose ◽  
Oxygen Ions

scholarly journals Transplantation of Endothelial Progenitor Cells in the Treatment of Coronary Artery Microembolism in Rats

2020 ◽  
Vol 29 ◽  
pp. 096368972091268
Author(s):  
Yajun Xue ◽  
Boda Zhou ◽  
Jian Wu ◽  
Guobin Miao ◽  
Kun Li ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cardiac Function ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Low Dose ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
High Dose ◽  
Endothelial Progenitor ◽  
Ventricular Ejection Fraction

As the impairment of myocardial microenvironments due to coronary microembolization (CME) compromises the treatment effect of percutaneous coronary intervention and leads to adverse prognosis, we hypothesized that endothelial progenitor cells (EPCs) transplantation could improve cardiac function in the condition of CME. Low- (2 × 105) and high- (2 × 106) dose rat bone marrow-derived EPCs were transplanted in a model of CME. To develop a CME model, rats were injected with autologous micro-blood-clots into the left ventricle. Echocardiograph was examined before and 1, 7, and 28 days after EPC transplantation; serum cardiac troponin I (cTNI), von Willebrand factor (vWF), and cardiac microRNA expression were examined one day after EPCs transplantation. Heart morphology and vascular endothelial growth factor (VEGF), vWF, and basic fibroblast growth factor (bFGF) expression were examined one day after EPC transplantation. After 10 days of culture inductions, BM-EPCs have high purity as confirmed by flow cytometry. Cardiac function reflected by left ventricular ejection fraction significantly decreased after CME treatment and rescued by low-dose EPC. Compared to the sham group, cTNI and vWF serum levels increased significantly after CME treatment and rescued by low-dose EPC and high-dose EPC. Low-dose EPC treatment decreased myocardial necrosis and fibrosis and elevated cardiac expression of VEGF and vWF, while decreasing the cardiac expression of bFGF. Low-dose EPC treatment significantly suppressed cardiac expression of microRNA-19a but significantly enhanced microRNA-21, microRNA-214, and microRNA-486-3p expression. In conclusion, our results indicate that low-dose EPC transplantation may play a proangiogenic, antifibroblast, antifibrosis, and antinecrosis role and enhance cardiac function in a rat model of CME through a microRNA-related pathway.

scholarly journals Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

2010 ◽  
Vol 2010 ◽  
pp. 1-4
Author(s):  
Damian Franzen ◽  
Angelika Haus ◽  
Martin Hellmich
Keyword(s):  
Multiple Sclerosis ◽  
Heart Failure ◽  
Cardiac Function ◽  
Low Dose ◽  
Therapeutic Option ◽  
Clinical Signs ◽  
Cardiac Effect ◽  
Left Ventricular ◽  
History Taking ◽  
Dose Dependent

Immunosuppressive therapy is an established therapeutic option in patients suffering from multiple sclerosis (MS). In an open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after mitoxantrone therapy. Mitoxantrone (12 mg/m2) was administered intravenously at 3-month intervals. Before each infusion, cardiac function was assessed by history taking, resting electrocardiogram, and echocardiography. Whereas no patient experienced clinical signs of heart failure, left ventricular pump function decreased continuously during mitoxantrone therapy and did not recover after cessation. The presented data suggest a dose-dependent and long-lasting toxic cardiac effect of low-dose mitoxantrone therapy in MS.

scholarly journals Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit

2008 ◽  
Vol 10 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Erik Lipšic ◽  
B. Daan Westenbrink ◽  
Peter van der Meer ◽  
Pim van der Harst ◽  
Adriaan A. Voors ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Low Dose ◽  
Experimental Heart Failure

scholarly journals The Effects of Low-dose Empagliflozin on Cardiac Function in a Rat Model of Streptozotocin-induced Diabetes

2021 ◽  
Author(s):  
Zeynep Eilf Yesilyurt ◽  
Irem Karaomerlioglu ◽  
Betül Rabia Erdogan ◽  
Gaye Ozturk ◽  
Martin C Michel ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Low Dose ◽  
Contractile Response ◽  
Diabetic Rats ◽  
Diabetic Heart ◽  
Stroke Work ◽  
Sprague Dawley ◽  
Loop Analysis

Abstract Purpose: Diabetes mellitus is a metabolic disorder leading to cardiovascular complications. Both in vivo cardiac function and β-adrenoceptor (β-AR) mediated responsiveness have been demonstrated to be blunted in the diabetic heart. Sodium glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA) have shown cardioprotective effects in patients and in some animal models. In this study, we aimed to investigate the effects of low-dose EMPA (10 mg/kg/day) on in vivo cardiac function and β-AR-mediated contractile response in streptozotocin (STZ)-induced diabetic rats. Methods: 11-12 week old male Sprague Dawley rats were divided into 4 groups; control, EMPA-treated control, diabetic, EMPA-treated diabetic. Diabetes was induced by STZ injection (40 mg/kg, i.p.). After 13-16 weeks, some of the diabetic and control rats were treated with a low dose of EMPA (10 mg/kg/day, oral gavage, once a day) or vehicle for another 8 weeks. At study end, in vivo cardiac function was evaluated by pressure-volume loop analysis. β-AR mediated contractile response was determined using isoprenaline in papillary muscle preparations. Results: EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate, cardiac output, stroke work, +dp/dt and -dp/dt and increased isovolumic relaxation, whereas in vitro responses were reduced to a minor extent. Treatment with EMPA showed a trend for improvement of some but not all parameters. Conclusion: Our results indicate that low dose EMPA treatment had limited effects on cardiac impairment although it reduced blood glucose. Future studies with a higher dose and greater sample sizes could help to clarify the possible benefits of EMPA on the diabetic heart.

Sign in / Sign up

Export Citation Format

Share Document